AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentHealth Care
Neuromyelitis OpticaAquaporin 4Myelitis, TransverseAutoantibodiesDemyelinating Autoimmune Diseases, CNSMultiple SclerosisOptic NeuritisImmunoglobulin GOptic NerveSpinal CordOligoclonal BandsArea PostremaMethylprednisoloneParaneoplastic Syndromes, Nervous SystemMyelitisParaneoplastic Syndromes, OcularMagnetic Resonance ImagingAstrocytesRecurrenceComplement System ProteinsBulbar Palsy, ProgressiveReferral and ConsultationSuburban Population
NMOSDLiving with neuromyelitis optica spectrum disorderRelapses in neuromyelitis opticaAntibody positiveDisorders2023Myelin oligodendrocNeurologyAcuteOpticDiagnosisMiddle AgedFindingsAQP4AquaporinInflammatorySpinal CordPatientsMultipleTreatmentSyndromesSymptomsClinical trialsAssessmentLesionsYearsProminentFormDiscussionTrialMarket
NMOSD20
  • Neuromyelitis optica spectrum disorders (NMOSD), including neuromyelitis optica (NMO), are autoimmune diseases characterized by acute inflammation of the optic nerve (optic neuritis, ON) and the spinal cord (myelitis). (wikipedia.org)
  • PARIS - Vaccines may trigger relapses in patients with neuromyelitis optica spectrum disorder (NMOSD), but that risk is diminished if patients are on immunosuppressive therapy, researchers reported here. (medpagetoday.com)
  • From numerous disorders of the central nervous system, Neuromyelitis optica spectrum disorder (NMOSD) is the one. (selfgrowth.com)
  • Neuromyelitis optica spectrum disorder (NMOSD) is a disorder of the central nervous system that majorly affects the nerves of eyes (optic neuritis) and the spinal cord (myelitis). (selfgrowth.com)
  • NMOSD is also known as Devic's disease or Neuromyelitis optica (NMO) . (selfgrowth.com)
  • On June 27, 2019, eculizumab, or Soliris, became the first FDA approved treatment for anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) in adults. (clevelandclinic.org)
  • Neuromyelitis optica spectrum disease (NMOSD) is a debilitating autoimmune inflammatory demyelinating disease of the central nervous system. (iasp-pain.org)
  • In October 2022, detailed positive results from the Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS®(ravulizumab-cwvz) significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+)neuromyelitis optica spectrum disorder (NMOSD), compared to the external placebo arm from the pivotal SOLIRIS®PREVENT clinical trial. (abnewswire.com)
  • In June 2022, Alexion Pharmaceuticals initited a Phase II/III , open-label, historical-controlled,single-arm, multicenter study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, and safety of ravulizumab inchildren and adolescents with aquaporin-4 antibody positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder(NMOSD). (abnewswire.com)
  • In May 2022, Alexion Pharmaceuticals announced that ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint inCHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder. (abnewswire.com)
  • 2 3 4 5 6 ] However, a more recent population-based survey conducted in urban Mangalore has shown a prevalence of 8.3/100,000 for MS and 2.6/100,000 for neuromyelitis optic spectrum diseases (NMOSD). (lww.com)
  • Neuromyelitis optica spectrum disorder (NMOSD) is one of the autoimmune demyelinating disorders, which is thought to be triggered by viral infection. (aku.edu)
  • keywords = "Aquaporin 4 (AQP-4), Neuromyelitis optica spectrum disorder (NMOSD), Severe acute respiratory syndrome (SARS). (aku.edu)
  • Satralizumab is an interleukin 6 (IL-6) receptor inhibitor that works by decreasing protocol-defined relapse (PDR) risk in patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD). (mdnewsline.com)
  • Here we investigated whether the brain structural and functional connectivity alterations were involved in fatigue related to neuromyelitis optica spectrum disorder (NMOSD). (biomedcentral.com)
  • Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder affecting the central nervous system and associated with the presence of aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) [ 1 ]. (biomedcentral.com)
  • Cognitive impairment in neuromyelitis optica spectrum disorder (NMOSD) is not uncommon occurring independent from attacks and lesions. (gccair.org)
  • Although fatigue is a major symptom in patients with neuromyelitis optica spectrum disorder (NMOSD), the underlying mechanism remains unclear. (phoenixrising.me)
  • Background: Optic neuritis is a frequent finding in multiple sclerosis (MS) and in neuromyelitis optica spectrum disorder (NMOSD), as well as in Myelin-Oligodendrocyte Glycoprotein (MOG) -positive disease. (tau.ac.il)
  • Neuromyelitis optica spectrum disorder (NMOSD) is characterised by recurrent attacks of optic neuritis and transverse myelitis . (bvsalud.org)
Living with neuromyelitis optica spectrum disorder2
  • The PAN Foundation today opened a new financial assistance program for people living with neuromyelitis optica spectrum disorder. (panfoundation.org)
  • The National Organization for Rare Disorders estimates that between one and 10 of every 100,000 people are living with neuromyelitis optica spectrum disorder worldwide. (panfoundation.org)
Relapses in neuromyelitis optica1
  • Because of these results, a subsequent randomized, double-blinded, placebo-controlled phase III time-to-event trial over 4 years, Prevention of Relapses in Neuromyelitis Optica (PREVENT), was performed. (clevelandclinic.org)
Antibody positive2
  • Eculizumab was first studied in 14 AQP4 antibody positive neuromyelitis optica patients in an open-label trial. (clevelandclinic.org)
  • Headache, nausea, and dizziness were the most common side effects reported in the open label trial of eculizumab in APQ4 antibody positive neuromyelitis optica patients. (clevelandclinic.org)
Disorders3
  • Neuromyelitis optica spectrum disorders: a case of longitudinally extensive transverse myelitis. (ac.lk)
  • Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. (ox.ac.uk)
  • BackgroundRituximab (RTX) efficacy in patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (MOGADs) is still poorly understood, though it appears to be lower than in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSDs). (ox.ac.uk)
20231
  • " Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2023 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market. (abnewswire.com)
Myelin oligodendroc2
  • We searched PubMed and Medline for studies published during the last 10 years with the general term "optic neuritis" and specific terms like "typical optic neuritis," "atypical optic neuritis," "multiple sclerosis," "neuromyelitis optic neuritis," and "myelin oligodendrocyte glycoprotein antibody. (lww.com)
  • In neuromyelitis optica spectrum disorder, the immune system targets aquaporin 4, a protein that is present on astrocytes in the brain and particularly the spinal cord and optic nerves, or myelin oligodendrocyte glycoprotein (MOG), which is present on the myelin of oligodendrocytes in the same areas of the CNS and possibly other targets. (msdmanuals.com)
Neurology2
  • In a study published this month in Annals of Neurology , researchers from Osaka University have revealed that treatment with an antibody to a protein called repulsive guidance molecule-a (RGMa) dramatically improves symptoms of neuromyelitis optica , a devastating autoimmune disorder, in an experimental rat model. (medicalxpress.com)
  • One condition that had not been differentiated from MS was neuromyelitis optica, a condition that received minimal attention in textbooks of neurology, usually a footnote in chapters on MS. It was either believed to be very rare and many neurologists in western countries didn't believe that it was an independent disease, rather a severe form of MS. (sumairafoundation.org)
Acute1
  • Although he did not propose any diagnostic criteria, a convention was established that lack of relapses was essential for making a diagnosis of "Devic's disease", a condition that he referred to as acute neuromyelitis optica. (sumairafoundation.org)
Optic9
  • Neuromyelitis optica (NMO) is a severe demyelinating disease defined principally by its tendency to selectively affect optic nerves and the spinal cord causing recurrent attacks of blindness and paralysis. (nih.gov)
  • Neuromyelitis optica spectrum disorder, also known as Devic's disease and neuromyelitis optica, is a rare autoimmune disease where an individual's immune system reacts against its own cells in the central nervous system, mainly in the optic nerves and spinal cord, but sometimes in the brain. (panfoundation.org)
  • Neuromyelitis optica (NMO) is a devastating neurologic disease characterized by severe optic neuritis and transverse myelitis. (go.jp)
  • Neuromyelitis Optica (NMO) is a severe form of demyelinating disease, characterized by involvement of the optic nerve and spinal cord and presence of highly specific anti-aquaporin-4 (AQP4) antibody in the CSF. (radiologycases.my)
  • NeuroMyelitis Optica (NMO) is an autoimmune demyelinating disease that differs from multiple sclerosis in that the inflammatory attack is limited to the optic (eye) nerves and the spinal cord. (weillcornell.org)
  • Neuromyelitis optica spectrum disorder is a rare CNS autoimmune disease, resulting in lesions throughout the optic nerves and spinal cord. (nursingrepository.org)
  • Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. (duke.edu)
  • can help differentiate neuromyelitis optica from other optic neuropathies. (msdmanuals.com)
  • Optic neuritis (ON) is a demyelinating inflammation of the optic nerve that often occurs in association with multiple sclerosis (MS) and, much less commonly, neuromyelitis optica (NMO). (medscape.com)
Diagnosis1
  • This antibody facilitated rapid and early diagnosis of neuromyelitis optica, and identified a series of other clinical syndromes, including sev ere vomiting and hiccups, to name but one, that was a syndrome of neuromyelitis optica previously unrecognized before discovery of the aquaporin-4 antibody. (sumairafoundation.org)
Middle Aged1
  • My first contact with a patient who raised the issue of what neuromyelitis optica might be was a middle-aged Lebanese woman for whom I cared while practicing at the Ottawa General Hospital in Ottawa, Canada, the site of my first neurological practice. (sumairafoundation.org)
Findings2
  • Findings in neuromyelitis optica spectrum disorder include reduced amplitudes or prolonged latencies. (msdmanuals.com)
  • Seropositive findings for neuromyelitis optica (NMO)-immunoglobulin G (IgG) antibody occurring with SS/SLE (Sjogren syndrome/SLE overlap) or non-organ-specific antibodies favors coexisting NMO (Devin syndrome) rather than a vasculitic process. (medscape.com)
AQP41
  • Long-term efficacy of satralizumab in AQP4-IGG-Seropositive Neuromyelitis Optica Spectrum Disorder from SAkuraSky and SAkuraStar. (mdnewsline.com)
Aquaporin3
  • Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: A case report. (iasp-pain.org)
  • Moreover, it was found that this Aquaporin 4 antibody was responsible for the Oriental form of Neuromyelitis optica. (diagnosticdetectives.com)
  • Neuromyelitis optica spectrum disorder is a demyelinating disorder that predominantly affects the eyes and spinal cord but can affect other structures in the central nervous system (CNS) that contain aquaporin 4. (msdmanuals.com)
Inflammatory1
  • Neuromyelitis optica (NMO) is an inflammatory disorder that can cause pain, paralysis, and even death. (medicalxpress.com)
Spinal Cord1
  • Neuromyelitis optica affects several (typically ≥ 3) contiguous spinal segments of the spinal cord, whereas MS typically affects a single segment. (msdmanuals.com)
Patients3
  • Patients who qualify are eligible to receive $9,600 per year in financial assistance to pay for the deductibles, copays, and coinsurance costs associated with their treatment for neuromyelitis optica spectrum disorder. (panfoundation.org)
  • While some reports in the early 1900's including a few patients in a thesis by a student of Devic had relapsing forms of neuromyelitis optica, the possibility of relapse in this condition was ignored and it was suggested that such patients may have represented diagnostic errors. (sumairafoundation.org)
  • The prevalence, incidence, and clinical assessment of neuromyelitis optica spectrum disorder in patients with demyelinating diseases. (bvsalud.org)
Multiple2
Treatment5
  • There is no cure for neuromyelitis optica spectrum disorder, but with proper treatment, long-term remission is sometimes possible. (panfoundation.org)
  • Be getting treatment for neuromyelitis optica spectrum disorder. (panfoundation.org)
  • The European Medicines Agency has granted orphan drug designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder. (fdanews.com)
  • Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuromyelitis Optica Spectrum Disorder pipeline constitutes 15+ key companies continuously working towards developing 15+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. (abnewswire.com)
  • Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years. (abnewswire.com)
Syndromes1
Symptoms2
  • Symptoms of neuromyelitis optica spectrum disorder include visual loss, muscle spasms, paraparesis or quadriparesis, and incontinence. (msdmanuals.com)
  • México: hallazgo del Amblyomma cajennense influenza-like symptoms, which continued after his return naturalmente infectado en Veracruz. (cdc.gov)
Clinical trials2
  • Q. What did the clinical trials of eculizumab in neuromyelitis optica show? (clevelandclinic.org)
  • Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- NDC-1308, AIM Biologicals, B001, LP-168, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years. (abnewswire.com)
Assessment2
  • The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. (abnewswire.com)
  • Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. (abnewswire.com)
Lesions1
  • On MRI, cerebral white matter lesions are uncommon in neuromyelitis optica, unlike in MS. (msdmanuals.com)
Years3
  • The report's author has thoroughly examined the market and concluded that the Neuromyelitis Optica Drug Market's growth will level off in the coming years. (timestechpharma.com)
  • The global Neuromyelitis Optica Drug Market research report is the well-analyzed solution for the decision-makers and academicians who are seeking a detailed analysis in terms of both qualitative as well as quantitative, for the historic period and for the upcoming years forecast. (timestechpharma.com)
  • Kevin O Neil was diagnosed with Neuro Myelitis Optica 5 years ago and know just how disabling the condition can be, during several attacks he lost vision in both eyes and was paralysed from the waist down. (nmouk.nhs.uk)
Prominent1
  • In addition to that, the prominent qualitative information added in the report includes Neuromyelitis Optica Drug Market trends, segmentation, key companies, SWOT, PORTER and PEST analysis, market maturity, value chain analysis, and others. (timestechpharma.com)
Form2
Discussion1
Trial1
  • Dr. Hopkins would also like to disclose that she's the site principal investigator for clinical trial of SA237 in neuromyelitis optica spectrum disorder. (cdc.gov)
Market2
  • According to Ameco Research's Neuromyelitis Optica Drug Market report, The analysts took this into account when estimating the Neuromyelitis Optica Drug Market size and CAGR for the respective industry. (timestechpharma.com)
  • The Neuromyelitis Optica Drug Market is finely segmented by considering the most important and responsive aspects of the respective market. (timestechpharma.com)